Anders Bjorklund
Overview
Explore the profile of Anders Bjorklund including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
148
Citations
8700
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fiorenzano A, Storm P, Sozzi E, Bruzelius A, Corsi S, Kajtez J, et al.
Proc Natl Acad Sci U S A
. 2024 Nov;
121(47):e2410331121.
PMID: 39541349
Dopaminergic (DA) neurons exhibit significant diversity characterized by differences in morphology, anatomical location, axonal projection pattern, and selective vulnerability to disease. More recently, scRNAseq has been used to map DA...
2.
Barker R, Bjorklund A, Parmar M
Bioessays
. 2024 Jul;
46(12):e2400118.
PMID: 39058892
Parkinson's disease (PD) is characterized by the loss of the dopaminergic nigrostriatal pathway which has led to the successful development of drug therapies that replace or stimulate this network pharmacologically....
3.
Bjorklund A, Mattsson B
J Parkinsons Dis
. 2024 Jul;
14(6):1077-1094.
PMID: 39031386
Targeted delivery of α-synuclein using AAV vectors has over the two decades since its introduction developed into a versatile tool for modeling different aspects of synucleinopathy, mimicking those seen in...
4.
The basal forebrain cholinergic system as target for cell replacement therapy in Parkinson's disease
Bjorklund A, Barker R
Brain
. 2024 Jan;
147(6):1937-1952.
PMID: 38279949
In recent years there has been a renewed interest in the basal forebrain cholinergic system as a target for the treatment of cognitive impairments in patients with Parkinson's disease, due...
5.
Kirkeby A, Nelander J, Hoban D, Rogelius N, Bjartmarz H, Storm P, et al.
Cell Stem Cell
. 2023 Oct;
30(10):1299-1314.e9.
PMID: 37802036
Cell replacement therapies for Parkinson's disease (PD) based on transplantation of pluripotent stem cell-derived dopaminergic neurons are now entering clinical trials. Here, we present quality, safety, and efficacy data supporting...
6.
Barker R, Bjorklund A
Handb Clin Neurol
. 2023 Feb;
193:211-226.
PMID: 36803812
One of the core pathological features of Parkinson's disease (PD) is the loss of the dopaminergic nigrostriatal pathway which lies at the heart of many of the motor features of...
7.
Bjorklund A, Nilsson F, Mattsson B, Hoban D, Parmar M
J Parkinsons Dis
. 2022 Oct;
12(8):2307-2320.
PMID: 36189605
Injections of pre-formed α-synuclein fibrils (PFFs) or overexpression of α-synuclein using AAV vectors are commonly used as models of Parkinson-like synucleinopathy in rats and mice. In the modified method reviewed...
8.
Bjorklund A, Bloem B, Brundin P, Federoff H
J Parkinsons Dis
. 2021 Sep;
11(s2):S123-S125.
PMID: 34569978
No abstract available.
9.
Barker R, Bjorklund A, Frucht S, Svendsen C
J Parkinsons Dis
. 2021 Aug;
11(3):909-917.
PMID: 34334425
The use of stem cell-derived dopamine neurons or deep brain stimulation (DBS) represents two alternative approaches to treat Parkinson's Disease. DBS is a widely used FDA-approved treatment and stem cell-derived...
10.
Parmar M, Bjorklund A, Bjorklund T
Curr Opin Genet Dev
. 2021 Jun;
70:76-82.
PMID: 34175529
Recent advances in cell reprogramming have made it possible to form new therapeutic cells within the body itself via a process called direct conversion or lineage reprogramming. A series of...